Mundipharma International Limited
https://www.mundipharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mundipharma International Limited
Why Global Pull Incentives Matter For AMR Drugs
The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.
Marching On: Eight Novel Agents Among March Goal Dates For US FDA
Crowded calendar could bring to an end the slow start for novel approvals in 2024, as decisions come due for Lilly’s donanemab, Merck’s sotatercept, Regeneron’s odronextamab and more.
China In-Licensing Crossroads: Zai Lab, Everest March Towards Market But BioNova Returns Rights
China's Zai Lab and Everest are still pursuing profitability on the commercialization of in-licensed assets, while BioNova and others have already bowed out of the game.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
-
Drug Delivery
- Controlled Release
- Other Names / Subsidiaries
-
- Cinfa Biotech GmbH
- Mundipharma Biologics S.L.
- Mundipharma EDO GmbH
- Napp Pharmaceuticals Ltd.
- Tolmar Australia Pty. Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice